N. Wizla

发表

The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening

E. Génin, C. Clavel, S. Leroy, 2009, Journal of Medical Genetics.

Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening.

I. Sermet-Gaudelus, M. Audrézet, E. Girodon, 2017, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

S. Leroy, A. Duhamel, G. Gargala, 2018, Mycopathologia.

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

J. Benichou, P. Reix, I. Pin, 2021, Pulmonary Therapy.

[Reproducibility of the shuttle walk test in children with cystic fibrosis].

F. Gottrand, R. Matran, L. Béghin, 2003, Revue des maladies respiratoires.

Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis (cid:1)

C. Cracowski, B. Wallaert, I. Sermet-Gaudelus, 2009 .

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis

P. Berger, I. Pin, B. Wallaert, 2020, Scientific Reports.

Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study

P. Varlet, I. Iwanicki-Caron, C. Elie, 2017, Journal of Crohn's & colitis.

Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.

J. Ledent, P. Varlet, I. Iwanicki-Caron, 2018, Inflammatory bowel diseases.

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

C. Goss, H. Rodgers, P. Burgel, 2020, Journal of Cystic Fibrosis.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

D. Caimmi, A. Didier, S. Leroy, 2020, American journal of respiratory and critical care medicine.

Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis

C. Cracowski, B. Wallaert, I. Sermet-Gaudelus, 2009, Antimicrobial Agents and Chemotherapy.

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis

P. Berger, I. Pin, B. Wallaert, 2020, Scientific Reports.

Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis

C. Cracowski, B. Wallaert, I. Sermet-Gaudelus, 2009 .

A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children

D. Turck, A. Munck, F. Huet, 2010 .

Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

I. Iwanicki-Caron, F. Vasseur, G. Savoye, 2016, Gut.

Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis

P. Reix, E. Kerem, I. Sermet-Gaudelus, 2023, American journal of respiratory and critical care medicine.

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

C. Goss, H. Rodgers, P. Burgel, 2022, Journal of Cystic Fibrosis.

Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis

H. Corvol, S. Benaboud, F. Chédevergne, 2024, The Lancet.